Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus
Prairie Educational and Research Cooperative, Department of Pharmacology, Southern Illinois School of Medicine, Springfield, USA
,
Prairie Educational and Research Cooperative, Springfield, USA
1 Prairie Educational and Research Cooperative, Department of Pharmacology, Southern Illinois School of Medicine, Springfield, USA
2 Prairie Educational and Research Cooperative, Springfield, USA
Magnesium deficiency is common in patients with type 2 diabetes mellitus (type 2 DM). When adequate magnesium supplementation is chronically given, patients with type 2 DM appear to have improved glucose control and may have delayed chronic complications. In addition, magnesium supplementation may slow the progression of chronic kidney disease (CKD) and decrease the risk of contrast-induced nephropathy in patients with type 2 DM. Keeping serum magnesium at 2.0 mEq/L or greater appears to accomplish these benefits for patients with type 2 DM. Periodically measuring serum magnesium and estimated glomerular filtration rate (eGFR) allows a physician to adjust the supplemental magnesium dose to accomplish these therapeutic goals while avoiding hypermagnesemia.
Mosley (2008) Deficiency #4: Magnesium. Cortlandt Forum—A Physician’s Magazine for Exchange of Ideas, Nov/Dec, 25-26.
Nadler, J.L., Buchanan, T., Natarajan, R., et al. (1993) Magnesium Deficiency Produces Insulin Resistance and Increased Thromboxane Synthesis. Hypertension, 21, 1024-1029. https://doi.org/10.1161/01.HYP.21.6.1024
Ruda, R.K. (1998) Magnesium Deficiency: A Cause of Heterogeneous Disease in Humans. Journal of Bone and Mineral Research, 13, 749-758. https://doi.org/10.1359/jbmr.1998.13.4.749
Wacker, W.E. and Parisi, A.F. (1968) Magnesium Metabolism. The New England Journal of Medicine, 278, 712-717. https://doi.org/10.1056/NEJM196803282781306
Schechter, M., Merz, C.N., Paul-Labrador, M., et al. (1999) Oral Magnesium Supplementation Inhibitors Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease. The American Journal of Cardiology, 84, 152-156. https://doi.org/10.1016/S0002-9149(99)00225-8
He, K., Liu, K., Daviglus, M.L., et al. (2006) Magnesium Intake and Incidence of Metabolic Syndrome among Young Adults. Circulation, 113, 1675-1682. https://doi.org/10.1161/CIRCULATIONAHA.105.588327
Nadler, J.L. (2004) A New Dietary Approach to Reduce the Risk of Type 2 Diabetes? Diabetes Care, 27, 270-271. https://doi.org/10.2337/diacare.27.1.270
Lima, M.D.L., Cruz, T., Pousada, J.C., et al. (1998) The Effect of Magnesium Supplementation in Increasing Doses on the Control of Type 2 Diabetes. Diabetes Care, 21, 682-686. https://doi.org/10.2337/diacare.21.5.682
Bokhari, S.R., Siriki, R., Teran, F.J., et al. (2018) Fatal Hypermagnesemia Due to Laxative Use. The American Journal of the Medical Sciences, 355, 390-395. https://doi.org/10.1016/j.amjms.2017.08.013
Dunn, M.J. and Walser, M. (1966) Magnesium Depletion in Normal Man. Metabolism, 15, 884-895. https://doi.org/10.1016/0026-0495(66)90159-4
Fitzgerald, M.G. and Fourman, P. (1956) An Experimental Study of Magnesium Deficiency in Man. Clinical Science, 15, 635-647.
Shafik, I.M. and Quamme, G.A. (1989) Early Adaption of Renal Magnesium Reabsorption in Response to Magnesium Restriction. American Journal of Physiology, 257, F974-F977. ttps://doi.org/10.1152/ajprenal.1989.257.6.F974
(2017) Safety of Long-Term PPI Use. JAMA, 318, 1177-1178. https://doi.org/10.1001/jama.2017.13272
Pham, P.C.T., Pham, P.M.T., Pham, P.A.T., et al. (2005) Lower Serum Magnesium Levels Are Associated with More Rapid Decline of Renal Function in Patients with Diabetes Mellitus Type 2. Clinical Nephrology, 63, 429-436. https://doi.org/10.5414/CNP63429
Katholi, R.E. (2006) Contrast-Induced Nephropathy—Update and Practical Clinical Applications. US Cardiology, 3, 73-80. https://doi.org/10.15420/usc.2006.3.2.73
Katholi, R.E. and Katholi, C.R. (2011) Contrast-Induced Nephropathy in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: Update and Practical Clinical Applications. In: Kirac, S.F., Ed., Advances in the Diagnosis of Coronary Atherosclerosis, IntechOpen Ltd., London, 235-254.
Hardiek, K.J., Katholi, R.E., Robbs, R.S. and Katholi, C.E. (2008) Renal Effects of Media in Diabetic Patients Undergoing Diagnostic or Interventional Coronary Angiography. Journal of Diabetes and Its Complications, 22, 171-177. https://doi.org/10.1016/j.jdiacomp.2006.11.002
June, C.H., Thompson, C.B., Kennedy, M.S., Loughran, T.P.J.R. and Deeg, H.J. (1986) Correlation of Hypomagnesemia with the Onset of Cyclosporine-Associated Hypertension in Marrow Transplant Patients. Transplantation, 41, 47-51. https://doi.org/10.1097/00007890-198601000-00009
Schilsky, R.L. and Anderson, T. (1979) Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin. Annals of Internal Medicine, 90, 929-931. https://doi.org/10.7326/0003-4819-90-6-929
Lajer, H. and Daugaard, G. (1999) Cisplatin and Hypomagnesemia. Cancer Treatment Reviews, 25, 47-58. https://doi.org/10.1053/ctrv.1999.0097
Li, F., Livingston, M.J. and Dong, Z. (2017) Protection of Kidneys by Magnesium in Cisplatin Chemotherapy: A Fight between Two Metals. American Journal of Physiology-Renal Physiology, 313, F955-F956. ttps://doi.org/10.1152/ajprenal.00294.2017
Katholi, R.E., Woods, W.T., Taylor, G.J., et al. (1998) Oxygen Free Radicals and Contrast Nephropathy. American Journal of Kidney Diseases, 32, 64-71. https://doi.org/10.1053/ajkd.1998.v32.pm9669426
Crandall, J.P., Mather, K., Rajpathak, S.N., et al. (2017) Statin Use and Risk of Diabetes: Results from the Diabetes Prevention Program. BMJ Open Diabetes Research & Care, 5, e000438. https://doi.org/10.1136/bmjdrc-2017-000438
Preiss, D., Seshasal, S.R., Welsh, P., et al. (2011) Risk of Incident Diabetes with Intensive-Dose Compared with Moderate-Dose Statin Therapy: A Meta-Analysis. JAMA, 305, 2556-2564. https://doi.org/10.1001/jama.2011.860
Wang, K.L., Liu, C.J., Chao, T.F., et al. (2014) Risk of New-Onset Diabetes Mellitus versus Reduction in Cardiovascular Events with Statin Therapy. The American Journal of Cardiology, 113, 631-636. ps://doi.org/10.1016/j.amjcard.2013.10.043
Hoogwerf, B.J. (2023) Statins May Increase Diabetes, but Benefit Still Outweighs Risk. Cleveland Clinic Journal of Medicine, 90, 53-62. https://doi.org/10.3949/ccjm.90a.22069
Mervaala, E.M.A., Himberg, J.J., Laakso, J., Tuomainen, P. and Karppanen, H. (1992) Beneficial Effects of a Potassium- and Magnesium-Enriched Salt Alternative. Hypertension, 19, 535-540. https://doi.org/10.1161/01.HYP.19.6.535
Whelton, P.K., He, J., Cutler, J.A., et al. (1997) Effects of Oral Potassium on Blood Pressure. Meta-Analysis of Randomized Controlled Clinical Trials. JAMA, 277, 1624-1632. https://doi.org/10.1001/jama.1997.03540440058033
Svetkey, L.P., Simons-Morton, D., Vollmer, W., et al. (1999) Effects of Dietary Patterns on Blood Pressure: Subgroup Analysis of the Dietary Approaches to Stop Hypertension (DASH) Randomized Clinical Trial. Archives of Internal Medicine, 159, 285-293. https://doi.org/10.1001/archinte.159.3.285
Agarwal, R. (2008) Hypertension, Hypokalemia and Thiazide-Induced Diabetes—A 3-Way Connection. Hypertension, 52, 1012-1013. https://doi.org/10.1161/HYPERTENSIONAHA.108.121970
Hu, G., Lindström, J., Valle, T.T., et al. (2004) Physical Activity, Body Mass Index and Risk of Type 2 Diabetes in Patients with Normal or Impaired Glucose Regulation. Archives of Internal Medicine, 164, 892-896. https://doi.org/10.1001/archinte.164.8.892
Jain, P., Hejjaji, V., Thomas, M.B., et al. (2022) Use of Primary Bariatric Surgery among Patients with Obesity and Diabetes. Insights from the Diabetes Collaborative Registry. International Journal of Obesity, 46, 2163-2167. https://doi.org/10.1038/s41366-022-01217-w
Torres, C.Y. and Katholi, R.E. (2014) Novel Treatment Approaches in Hypertensive Type 2 Diabetes Patients. World Journal of Diabetes, 5, 536-545. https://doi.org/10.4239/wjd.v5.i4.536
Bakris, G.L., Forseca, V., et al. (2004) Metabolic Effects of Carvedilol vs Metoprolol in Patients with Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial. JAMA, 292, 2227-2236. https://doi.org/10.1001/jama.292.18.2227
Katholi, R.E. and Ervin, M.R. (2023) Cardiac Rhythm Implications of Extracellular Magnesium. Cardiology & Vascular Research, 7, 1-9.
Peacock, J.M., Ohira, T., Post, W., et al. (2010) Serum Magnesium and Risk of Sudden Cardiac Death in the Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal, 160, 464-470. https://doi.org/10.1016/j.ahj.2010.06.012
Zoler, M.L. (2022) Experts Elevate New Drugs for Diabetic Kidney Disease. Internal Medicine News.
The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 388, 117-127. https://doi.org/10.1056/NEJMoa2204233
Perkovic, V., Jardine, M.J., Neal, B., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380, 2295-2306. https://doi.org/10.1056/NEJMoa1811744
Palmer, B.F. and Clegg, D.J. (2022) Kidney-Protective Effects of SGLT2 Inhibitors. Clinical Journal of the American Society of Nephrology, 18, 279-289. https://doi.org/10.2215/CJN.09380822
Bakris, G.L., Agarwal, R., Anker, S.D., et al. (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845
August, P. (2023) Chronic Kidney Disease—Another Step Forward. The New England Journal of Medicine, 388, 179-180. https://doi.org/10.1056/NEJMe2215286
Ng, H.Y., Kuo, W.H., Tain, Y.L., et al. (2021) Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome. Nutrients, 13, Article 4088. https://doi.org/10.3390/nu13114088
Ray, E.C., Boyd-Shiwarski, C.R., Liu, P.F., Novacic, D. and Cassiman, D. (2020) SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients. Kidney Medicine, 2, 359-364. https://doi.org/10.1016/j.xkme.2020.01.010
U.S. Department of Health & Human Services, National Institutes of Health, DPCCPSI, Office of Dietary Supplements, Strengthening Knowledge and Understanding of Dietary Supplements. Magnesium Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional
Pardo, M.R., Vilar, E.G., et al. (2021) Bioavailability of Magnesium Food Supplements: A Systematic Review. Nutrition, 89, Article ID: 111294. https://doi.org/10.1016/j.nut.2021.111294
Ware, M. (2020) Why Do We Need Magnesium? https://www.medicalnewstoday.com/articles/286839#drug-interactions